No clear answer
Azathioprine: reduce relapses and new lesions in relapsing MS
relapsing MS · Broad immunosuppression / cytotoxics
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 1
These linked trials do not set the status.
- M.A.I.N. trialShown as good as comparator
Phase 3 · 2007 · Compared with interferon beta-1a, interferon beta-1b
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Results pending to No clear answer
- 2026-10-27First listed as Results pending
Related hypotheses
- Cyclophosphamide anhydrous: slow disability worsening in relapsing MS
- Mitoxantrone: slow disability worsening in relapsing MS
- Azathioprine: prevent attacks in MOGAD
- Azathioprine: prevent attacks in NMOSD
- Cyclophosphamide anhydrous: reduce relapses and new lesions in relapsing MS
- Methotrexate: reduce relapses and new lesions in relapsing MS
- Mycophenolate mofetil: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error